|
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Clinical research trials and Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas. Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas clinical trial. Human subjects often get the best healthcare possible for their Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas  Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
For Condition: untreated childhood brain stem glioma
Status: Recruiting
Sponsor(s): Pediatric Brain Tumor Consortium , National Cancer Institute (NCI)
Synopsis: RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the effectiveness of combining gefitinib with radiation therapy in treating children who have newly diagnosedglioma.
Details: OBJECTIVES: - Determine the safety and maximum tolerated dose of gefitinib when combined with brain irradiation in children with newly diagnosed brain stem gliomas or incompletely resected supratentorial malignant gliomas (STMG) who are not receiving concurrent enzyme-inducing anticonvulsant drugs (EIACDs). (Phase I closed to accrual effective 10/27/2003). - Determine the safety of this regimen in children with newly diagnosed incompletely resected STMG who are receiving concurrent EIACDs. (Phase I closed to accrual effective 10/27/2003). - Determine the safety and efficacy of this regimen in children with newly diagnosed poor-prognosis brain stem glioma. - Correlate the hemodynamic MRI parameters to metabolic fludeoxyglucose F 18-positron emission tomography scanning with clinical response or progression in patients treated with this regimen. - Determine the pharmacokinetics of gefitinib, including the effects of EIACDs on the pharmacokinetics of this drug, in these patients. OUTLINE: This is a multicenter, dose-escalation study of gefitinib (Phase I closed to accrual effective 10/27/2003). Patients are stratified according to the following: - Stratum 1A: Intrinsic brain stem glioma; not receiving concurrent enzyme-inducing anticonvulsant drugs (EIACDs) - Stratum 1B: Incompletely resected supratentorial malignant gliomas (STMG); not receiving concurrent EIACDs - Stratum 2: Incompletely resected STMG; receiving concurrent EIACDs - Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. - Phase II portion (patients in stratum 1A): Once the MTD is determined, additional patients are treated at the MTD. Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 170 patients (120 for stratum 1A and 50 for strata 1B and 2 combined) will be accrued for this study within 2 years. (Phase I closed to accrual effective 10/27/2003). A total of 40 patients will be accrued for phase II of this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 3 Years/21 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of 1 of the following: - Newly diagnosed non-disseminated diffuse intrinsic brain stem glioma (BSG) - Newly diagnosed incompletely resected supratentorial malignant glioma, including anaplastic astrocytoma, glioblastoma multiforme, or other high-grade gliomas (Phase I closed to accrual effective 10/27/2003) - Must have residual tumor by postoperative MRI or CT scan - Bone marrow involvement by disease allowed - No disseminated disease - No spinal disease requiring radiotherapy - No evidence of intratumoral hemorrhage PATIENT CHARACTERISTICS: Age - 3 to 21 Performance status - Karnofsky 50-100% OR - Lansky 50-100% Life expectancy - Not specified Hematopoietic - Absolute neutrophil count greater than 1,000/mm^3 * - Platelet count greater than 100,000/mm^3 * - Hemoglobin greater than 8 g/dL (transfusion allowed) NOTE: *Transfusion independent Hepatic - Bilirubin no greater than 1.5 times normal - ALT less than 3 times normal - Albumin at least 2 g/dL - No significant hepatic disease Renal - Creatinine less than 2 times normal OR - Glomerular filtration rate greater than 70 mL/min - No significant renal disease Cardiovascular - No significant cardiac disease - No deep venous or arterial thrombosis within the past 6 weeks Pulmonary - No significant pulmonary disease Other - No uncontrolled infection - No significant gastrointestinal disease - No significant psychiatric disease - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for at least 6 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy - More than 2 weeks since prior colony-stimulating growth factors (e.g., filgrastim [G-CSF], sargramostim [GM-CSF], or epoetin alfa) - No prior bone marrow transplantation Chemotherapy - No prior chemotherapy Endocrine therapy - Concurrent corticosteroids allowed if receiving a stable or decreasing dose for at least 1 week before study entry - No concurrent tamoxifen Radiotherapy - See Disease Characteristics - No prior radiotherapy Surgery - See Disease Characteristics - No concurrent neurosurgical procedures for reasons other than progression (e.g., onset of hydrocephalus) Other - No prior gefitinib - No other concurrent anticancer or experimental drug therapy - No concurrent drugs with known corneal toxicity (e.g., chlorpromazine, amiodarone, or chloroquine) - No concurrent enzyme-inducing anticonvulsant drugs for patients with BSG
Total Enrollment:
Location and Contact Information:
Overall Study Official:
J.Geyer, Study Chair, Children's Hospital and Medical Center - Seattle
Children's National Medical Center *Recruiting*
Washington D.C., District of Columbia, 20010-2970
United States
Recruiting Roger Packer 202-884-2120
UCSF Comprehensive Cancer Center *Recruiting*
San Francisco, California, 94115
United States
Recruiting Michael Prados 415-353-9510
Children's Hospital and Regional Medical Center - Seattle *Recruiting*
Seattle, Washington, 98105
United States
Recruiting J. Geyer 206-987-6664
St. Jude Children's Research Hospital *Recruiting*
Memphis, Tennessee, 38105-2794
United States
Recruiting Larry Kun 901-495-3565
Duke Comprehensive Cancer Center *Recruiting*
Durham, North Carolina, 27710
United States
Recruiting Henry Friedman 919-684-5301
Children's Memorial Hospital - Chicago *Recruiting*
Chicago, Illinois, 60614
United States
Recruiting Stewart Goldman 773-880-4598 ext. 3270
Children's Hospital of Philadelphia *Recruiting*
Philadelphia, Pennsylvania, 19104-4318
United States
Recruiting Peter Phillips 215-590-2107
Texas Children's Cancer Center *Recruiting*
Houston, Texas, 77030-2399
United States
Recruiting Susan Blaney 832-822-4215
Children's Hospital of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213
United States
Recruiting Ian Pollack 412-692-5881
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Mark Kieran 617-632-4907
Additional Information:
Study ID Numbers: CDR0000069490; PBTC-007
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00042991
Other Untreated Childhood Brain Stem Glioma Studies:
1. Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas
2. Paclitaxel Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
3. Imatinib Mesylate With or Without Radiation Therapy in Treating Children With Newly Diagnosed or Recurrent Glioma
4. Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
5. Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Related Studies:
Other untreated childhood brain stem glioma Clinical Trials
Other Tennessee Clinical Trials
Other Memphis Clinical Trials
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
|
|
|
|
|
|
|
|
